191 related articles for article (PubMed ID: 34011479)
1. Efficacy and safety of albumin infusion for overt hepatic encephalopathy: A systematic review and meta-analysis.
Teh KB; Loo JH; Tam YC; Wong YJ
Dig Liver Dis; 2021 Jul; 53(7):817-823. PubMed ID: 34011479
[TBL] [Abstract][Full Text] [Related]
2. Beneficial effects of L-ornithine L-aspartate for prevention of overt hepatic encephalopathy in patients with cirrhosis: a systematic review with meta-analysis.
Butterworth RF
Metab Brain Dis; 2020 Jan; 35(1):75-81. PubMed ID: 31338724
[TBL] [Abstract][Full Text] [Related]
3. Albumin infusion may decrease the incidence and severity of overt hepatic encephalopathy in liver cirrhosis.
Bai Z; Bernardi M; Yoshida EM; Li H; Guo X; Méndez-Sánchez N; Li Y; Wang R; Deng J; Qi X
Aging (Albany NY); 2019 Oct; 11(19):8502-8525. PubMed ID: 31596729
[TBL] [Abstract][Full Text] [Related]
4. Development and validation of the AMMON-OHE model to predict risk of overt hepatic encephalopathy occurrence in outpatients with cirrhosis.
Ballester MP; Tranah TH; Balcar L; Fiorillo A; Ampuero J; Kerbert AJC; Thomsen KL; Escudero MD; Mandorfer M; Reiberger T; Shawcross DL; Romero-Gómez M; Montoliu C; Carbonell-Asins JA; Jalan R
J Hepatol; 2023 Oct; 79(4):967-976. PubMed ID: 37277075
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of L-ornithine L-aspartate for minimal hepatic encephalopathy in patients with cirrhosis: A meta-analysis of randomized controlled trials.
He Q; Mao C; Chen Z; Zeng Y; Deng Y; Hu R
Arab J Gastroenterol; 2024 May; 25(2):84-92. PubMed ID: 38403493
[TBL] [Abstract][Full Text] [Related]
6. Early-Recurrent Overt Hepatic Encephalopathy Is Associated with Reduced Survival in Cirrhotic Patients after Transjugular Intrahepatic Portosystemic Shunt Creation.
Zuo L; Lv Y; Wang Q; Yin Z; Wang Z; He C; Guo W; Niu J; Bai W; Li K; Yu T; Yuan X; Chen H; Liu H; Xia D; Wang E; Luo B; Li X; Yuan J; Han N; Nie Y; Fan D; Han G
J Vasc Interv Radiol; 2019 Feb; 30(2):148-153.e2. PubMed ID: 30638778
[TBL] [Abstract][Full Text] [Related]
7. Total area of spontaneous portosystemic shunts independently predicts hepatic encephalopathy and mortality in liver cirrhosis.
Praktiknjo M; Simón-Talero M; Römer J; Roccarina D; Martínez J; Lampichler K; Baiges A; Low G; Llop E; Maurer MH; Zipprich A; Triolo M; Maleux G; Fialla AD; Dam C; Vidal-González J; Majumdar A; Picón C; Toth D; Darnell A; Abraldes JG; López M; Jansen C; Chang J; Schierwagen R; Uschner F; Kukuk G; Meyer C; Thomas D; Wolter K; Strassburg CP; Laleman W; La Mura V; Ripoll C; Berzigotti A; Calleja JL; Tandon P; Hernandez-Gea V; Reiberger T; Albillos A; Tsochatzis EA; Krag A; Genescà J; Trebicka J;
J Hepatol; 2020 Jun; 72(6):1140-1150. PubMed ID: 31954206
[TBL] [Abstract][Full Text] [Related]
8. Pharmacotherapies that specifically target ammonia for the prevention and treatment of hepatic encephalopathy in adults with cirrhosis.
Zacharias HD; Zacharias AP; Gluud LL; Morgan MY
Cochrane Database Syst Rev; 2019 Jun; 6(6):CD012334. PubMed ID: 31204790
[TBL] [Abstract][Full Text] [Related]
9. Use of human albumin infusion in cirrhotic patients: a systematic review and meta-analysis of randomized controlled trials.
Bai Z; Wang L; Wang R; Zou M; Méndez-Sánchez N; Romeiro FG; Cheng G; Qi X
Hepatol Int; 2022 Dec; 16(6):1468-1483. PubMed ID: 36048318
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of IV albumin for non-spontaneous bacterial peritonitis infection among patients with cirrhosis: A systematic review and meta-analysis.
Wong YJ; Qiu TY; Tam YC; Mohan BP; Gallegos-Orozco JF; Adler DG
Dig Liver Dis; 2020 Oct; 52(10):1137-1142. PubMed ID: 32586766
[TBL] [Abstract][Full Text] [Related]
11. Effects of intravenous albumin in patients with cirrhosis and episodic hepatic encephalopathy: a randomized double-blind study.
Simón-Talero M; García-Martínez R; Torrens M; Augustin S; Gómez S; Pereira G; Guevara M; Ginés P; Soriano G; Román E; Sánchez-Delgado J; Ferrer R; Nieto JC; Sunyé P; Fuentes I; Esteban R; Córdoba J
J Hepatol; 2013 Dec; 59(6):1184-92. PubMed ID: 23872605
[TBL] [Abstract][Full Text] [Related]
12. Long-term albumin administration in patients with cirrhosis and ascites: A meta-analysis of randomized controlled trials.
Sandi BB; Leão GS; de Mattos AA; de Mattos ÂZ
J Gastroenterol Hepatol; 2021 Mar; 36(3):609-617. PubMed ID: 32914468
[TBL] [Abstract][Full Text] [Related]
13. Albumin in the management of hepatic encephalopathy: A systematic review and meta-analysis.
Is B; Bombassaro IZ; Tovo CV; de Mattos ÂZ; Ahlert M; Chiesa T; de Mattos AA
Ann Hepatol; 2021 Dec; 26():100541. PubMed ID: 34600143
[TBL] [Abstract][Full Text] [Related]
14. Impact of non-selective ß-blockers on hepatic encephalopathy in patients with liver cirrhosis.
Labenz C; Nagel M; Toenges G; Kuchen R; Schattenberg JM; Hilscher M; Huber Y; Marquardt JU; Labenz J; Galle PR; Wörns MA
Eur J Intern Med; 2020 Dec; 82():83-89. PubMed ID: 32873457
[TBL] [Abstract][Full Text] [Related]
15. [Retrospective analysis of risk factors of liver cirrhosis combined with overt hepatic encephalopathy: a single -center case-control study].
Fan YN; Ji TT; Liang RY; Yu YY; Xu JH
Zhonghua Gan Zang Bing Za Zhi; 2021 Feb; 29(2):133-136. PubMed ID: 33685081
[No Abstract] [Full Text] [Related]
16. Albumin administration in patients with decompensated liver cirrhosis: a meta-analytic update.
Ashour AA; Atta MA; Sadek KW; Obaid KR; Ashour MA; Ashour A; Danjuma MI; Doi SA; ElZouki AN
Eur J Gastroenterol Hepatol; 2021 Apr; 33(4):479-486. PubMed ID: 32976190
[TBL] [Abstract][Full Text] [Related]
17. Prediction of overt hepatic encephalopathy by the continuous reaction time method and the portosystemic encephalopathy syndrome test in clinically mentally unimpaired patients with cirrhosis.
Wernberg CW; Schaffalitzky de Muckadell OB; Vilstrup H; M Lauridsen M
PLoS One; 2019; 14(12):e0226283. PubMed ID: 31830113
[TBL] [Abstract][Full Text] [Related]
18. A double blind randomized controlled trial to assess efficacy of nutritional therapy for prevention of recurrence of hepatic encephalopathy in patients with cirrhosis.
Ahuja H; Sharma BC; Sachdeva S; Mahajan B; Sharma A; Bara S; Srivastava S; Kumar A; Dalal A; Sonika U
J Gastroenterol Hepatol; 2023 Mar; 38(3):433-440. PubMed ID: 36574769
[TBL] [Abstract][Full Text] [Related]
19. Prophylactic Lactulose Therapy in Patients with Cirrhosis and Upper Gastrointestinal Bleeding: A Meta-analysis of Randomized Trials.
Roy A; Giri S; Singh A; Vaidya A; Angadi S
J Gastrointestin Liver Dis; 2023 Dec; 32(4):507-512. PubMed ID: 38147599
[TBL] [Abstract][Full Text] [Related]
20. L-Carnitine for the Treatment of Overt Hepatic Encephalopathy in Patients with Advanced Liver Cirrhosis.
Tajiri K; Futsukaichi Y; Kobayashi S; Yasumura S; Takahara T; Minemura M; Sugiyama T
J Nutr Sci Vitaminol (Tokyo); 2018; 64(5):321-328. PubMed ID: 30381621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
